68.10.Z - Buying and selling of own real estate
21.10.Z - Manufacture of basic pharmaceutical substances
47.99.Z - Other retail sale not in stores, stalls or markets
64.20.Z - Activities of holding companies
68.20.Z - Rental and operating of own or leased real estate
70.22.Z - Business and other management consultancy activities
73.20.Z - Market research and public opinion polling
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
85.59 - Other education n.e.c.
86 - Human health activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | 0,5 | 1,2 | 3 | 156,9 |
Gross profit (loss) | 0,6 | 1,1 | 3 | 167,3 |
EBITDA | 0,7 | 2 | 4,4 | 116,5 |
Short time liabilities | 0,7 | 1,2 | 1,2 | -0,6 |
Other operating costs | 0 | 0 | 0 | -∞ |
Equity capital | 1,2 | 2,1 | 4,6 | 114,5 |
Operating profit (EBIT) | 0,6 | 1,2 | 3,1 | 162,4 |
Assets | 2 | 4,7 | 5,8 | 24 |
Net profit (loss) | 0,6 | 0,9 | 2,4 | 167,2 |
Cash | 1 | 0,2 | 1,6 | 592,9 |
Liabilities and provisions for liabilities | 0,7 | 2,5 | 1,2 | -52,1 |
Net income from sale | 7,7 | 11,2 | 16,9 | 51,3 |
Working assets | 1,9 | 2 | 4,3 | 122,6 |
Other income costs | 0,2 | 0 | 0,1 | -∞ |
Depreciation | 0 | 0,9 | 1,3 | 53,6 |
% | % | % | p.p. | |
Profitability of capital | 49,7 | 42,8 | 53,4 | 10,6 |
Equity capital to total assets | 62,4 | 45,7 | 79 | 33,3 |
Gross profit margin | 8,4 | 10,1 | 17,8 | 7,7 |
EBITDA Margin | 8,5 | 18,1 | 25,9 | 7,8 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 31 | 40 | 26 | -14 |
Current financial liquidity indicator | 2.8875670433044434 | 1.6049187183380127 | 3.5930075645446777 | 2 |
Net dept to EBITDA | -1.3950811624526978 | 0.5187602639198303 | -0.36252251267433167 | -0,9 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane